Fabry Disease Drugs Market Size 2032 | Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, and others

DelveInsight's "Fabry Disease Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Takeaways from the Fabry Disease Market Research Report
• The total Fabry Disease market size in the 7MM is approximately USD 1,306 million in 2022 and is projected to increase during the forecast period (2023-2032)
• Among EU countries, the UK and Italy account for the maximum market size of USD 158, and USD 150 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 44 million.
• Japan accounts for a market size of USD 125 million in 2022, but these dynamics are expected to change in the forecast period.
• There were 15,200+ diagnosed prevalent cases of Fabry Disease estimated to have occurred in the 7MM in 2022 of which 8,300+ of the accounted cases were estimated to be from the US alone and these cases are anticipated to increase during the forecast period.
• The diagnosed prevalent cases of Fabry Disease were further divided into Phenotype-specific cases. The Phenotype-specific diagnosed prevalent cases of Fabry Disease are categorized into Classic and Late-onset with 6,900+, and 8,300+ cases respectively in the 7MM in 2022 which will further increase in 2032.
• The leading Fabry Disease Companies such as Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech, GmBH, and others.
• Promising Fabry Disease Therapies such as AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine, 4D-310, AMT-191, AL01211, Pegunigalsidase Alfa, and others.

Discover which therapies are expected to grab the major Fabry disease market share @ Fabry Disease Market Size Report- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body. Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.

Fabry Disease Epidemiology Segmentation
• Prevalent Cases of Fabry Disease
• Age-specific Cases of Fabry Disease
• Gender-specific Cases of Fabry Disease
• Diagnosed Cases of Fabry Disease
• Phenotype-specific cases
• Treated Cases

Download the report to understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Epidemiological Insights- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fabry Disease Treatment Market
Fabry disease treatment includes enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatment such as ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics. Studies have shown ERT to delay, but not always prevent, some clinical complications of FD. Currently, effective Fabry disease management necessitates a multidisciplinary approach that includes intravenous ERT or chaperone therapy, as well as adjunct therapies such as lifestyle modifications and prophylactic medications.

Fabry Disease Pipeline Therapies and Key Companies
• PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: GREENOVATION BIOTECH GMBH

To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fabry Disease Market Dynamics
To counter the current unmet needs of the Fabry disease market and to provide better treatment options, several companies are working aggressively to develop new therapies with novel mechanisms of action. In addition, many therapies are being studied in various stages of clinical trials. Pegylated forms of -GAL, gene therapy, and substrate reduction therapy are examples of these.

Learn more about the FDA-approved drugs for Fabry disease treatment @ Drugs for Fabry Disease Treatment- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Fabry Disease Market Report
• Therapeutic Assessment: Fabry Disease's current marketed and emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Fabry Disease Market Access and Reimbursement

Discover more about drugs for Fabry disease in development @ Fabry Disease Clinical Trials- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Fabry Disease Market Report Introduction
3. Fabry Disease Market Overview At A Glance
4. Fabry Disease Epidemiology And Market Forecast Methodology
5. Key Events
6. Executive Summary Of Fabry Disease
7. Fabry Disease Market Disease Background And Overview
8. Fabry Disease Epidemiology And Patient Population
9. Fabry Disease Patient Journey
10. Fabry Disease Marketed Drugs
11. Fabry Disease Emerging Drugs
12. Fabry Disease: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Fabry Disease Swot Analysis
15. Fabry Disease Unmet Needs
16. Fabry Disease Market Access And Reimbursement
17. Appendix
18. Delveinsight Capabilities
19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.